Vetoquinol SA VETO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €94.40
- Day Range
- €93.50–95.60
- 52-Week Range
- €76.30–108.60
- Bid/Ask
- €93.70 / €94.60
- Market Cap
- €1.12 Bil
- Volume/Avg
- 1,012 / 2,910
Key Statistics
- Price/Earnings (Normalized)
- 15.96
- Price/Sales
- 2.11
- Dividend Yield (Trailing)
- 0.90%
- Dividend Yield (Forward)
- 0.90%
- Total Yield
- 0.90%
Company Profile
Vetoquinol SA operates is a France-based firm serving in the healthcare market. Its focus lies on developing and marketing veterinary drugs mainly in the European region and to a certain extent in America and Asia. Its portfolio of drugs entails anti-infectives, anti- pain inflammatory drugs, cardiovascular and nephrology treatment intended mainly for pets and livestock.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 2,483
- Website
- http://www.vetoquinol.com
Comparables
Valuation
|
Metric
|
VETO
|
MEDCL
|
AELIS
|
|---|---|---|---|
Price/Earnings (Normalized) | 15.96 | — | — |
Price/Book Value | 2.12 | — | 12.18 |
Price/Sales | 2.11 | 47.48 | 17.38 |
Price/Cash Flow | 12.61 | — | — |
Price/Earnings
VETO
MEDCL
AELIS
Financial Strength
|
Metric
|
VETO
|
MEDCL
|
AELIS
|
|---|---|---|---|
Quick Ratio | 1.82 | 1.91 | 2.38 |
Current Ratio | 2.61 | 1.99 | 2.48 |
Interest Coverage | 81.21 | −4.87 | −33.55 |
Quick Ratio
VETO
MEDCL
AELIS
Profitability
|
Metric
|
VETO
|
MEDCL
|
AELIS
|
|---|---|---|---|
Return on Assets (Normalized) | 8.73% | −63.12% | −14.59% |
Return on Equity (Normalized) | 11.46% | — | −28.94% |
Return on Invested Capital (Normalized) | 10.78% | −76.45% | −24.22% |
Return on Assets
VETO
MEDCL
AELIS
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Zoetis Inc Class A
ZTS
| Bzpxrmclhj | Jnh | $79.8 Bil | |||
| Merck KGaA ADR
MKKGY
| Cxhggqxyv | Gtkdg | $71.7 Bil | |||
| Haleon PLC ADR
HLN
| Ytmktpbb | Wpccl | $37.9 Bil | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Vrqfskznl | Wxrn | $13.0 Bil | |||
| Viatris Inc
VTRS
| Nmrtvwt | Wmjk | $12.3 Bil | |||
| Catalent Inc
CTLT
| Srmsznhn | Stxjxx | $10.3 Bil | |||
| Perrigo Co PLC
PRGO
| Shhkcfdbm | Wcxn | $3.5 Bil | |||
| Prestige Consumer Healthcare Inc
PBH
| Lcgqmmn | Qdkhdl | $3.4 Bil | |||
| Curaleaf Holdings Inc
CURLF
| Gfkncmkl | Rvqk | $2.8 Bil | |||
| Green Thumb Industries Inc
GTBIF
| Bplbntkj | Znfq | $2.7 Bil |